EMA
withdrawal
· 2012-08-15
EMA Withdrawn: MabCampath (alemtuzumab) — Genzyme Europe B.V.
Summary
EMA withdrew MabCampath (alemtuzumab) from the market.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Withdrawn. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Genzyme Europe B.V.. Decision date: 06/07/2001